Jump to section
To make healthcare work faster and smarter.
In the U.S, strokes are the third leading cause of death killing more than 140,000 people annually. These fatality rates are partially a result of strokes being hard to diagnose, and once they occur it is often too late.
Viz uses artificial intelligence to rapidly identify stroke victims to provide treatment faster, aiming to save lives and the financial costs associated with medical treatment. The company achieves this by using machine learning which is trained to identify anomalies within brain scans that neuroscientists struggle to spot.
With a valuation of over $1 billion, in 2023, Viz secured capital from pharmaceutical giant Bristol-Meyers-Squibbs to develop an AI algorithm and provider workflow focused on detecting hypertrophic cardiomyopathy. This is part of Viz's objective of branching out from a focus on strokes into new healthcare territory.
Kirsty
Company Specialist at Welcome to the Jungle
Mar 2023
$40m
GROWTH EQUITY VC
Apr 2022
$100m
SERIES D
This company has top investors
Dr Chris Mansi
(CEO)Was a Neurosurgeon for 4 years before co-founding EDUSURG, an online medical education platform for surgeons, where they also served as CEO.
David Golan
(CTO)Was an algorithm developer at b-hive networks and VMware, before becoming a Teaching Assistant at Tel Aviv University. Was also a Postdoctoral Fellow at Stanford.
Product
Finance, Legal & Compliance
Sales & Account Management